AbbVie Inc.

ABBV

US00287Y1091

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

2024-07-14 - Détachement de

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

168.1 USD

Average target price

183.3 USD

Spread / Average Target

+9.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+9.64%	297B
ELI LILLY AND COMPANY	+60.25%	846B
NOVO NORDISK A/S	+38.56%	628B
JOHNSON & JOHNSON	-4.49%	360B
MERCK & CO., INC.	+18.30%	322B
ASTRAZENECA PLC	+14.15%	240B
ROCHE HOLDING AG	+3.11%	224B
NOVARTIS AG	+16.98%	223B
AMGEN INC.	+12.87%	173B
PFIZER, INC.	-0.45%	161B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-07-11 pm EDT			5-day change	1st Jan Change
169.9 ^USD	+1.05%		+3.70%	+9.64%

Jul. 11	Morgan Stanley Adjusts Price Target on AbbVie to $196 From $191	MT
Jul. 10	Redburn Atlantic Adjusts Price Target on AbbVie to $203 From $207	MT

Morgan Stanley Adjusts Price Target on AbbVie to $196 From $191	Jul. 11	MT
Redburn Atlantic Adjusts Price Target on AbbVie to $203 From $207	Jul. 10	MT
Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer	Jul. 10	CI
Mixed feelings	Jul. 09
That's not so bad, is it?	Jul. 08
Sector Update: Health Care Stocks Steady Premarket Friday	Jul. 05	MT
AbbVie Flags Hit to Q2 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook	Jul. 05	MT
AbbVie cuts 2024 profit forecast	Jul. 03	RE
Merus Names New Chief Medical Officer	Jul. 01	MT
AbbVie: new CEO takes up post	Jul. 01	CF
AbbVie Says Robert Michael Assumes CEO Role	Jul. 01	MT
AbbVie Announces Board Changes	Jul. 01	CI
AbbVie Inc.(NYSE:ABBV) added to Russell Top 200 Value Index	Jun. 30	CI
AbbVie Inc.(NYSE:ABBV) added to Russell 3000 Value Index	Jun. 30	CI
AbbVie Inc.(NYSE:ABBV) added to Russell 1000 Value-Defensive Index	Jun. 30	CI
AbbVie Inc.(NYSE:ABBV) added to Russell 1000 Value Index	Jun. 30	CI
AbbVie Inc.(NYSE:ABBV) added to Russell 3000E Value Index	Jun. 30	CI
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	Jun. 28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	Jun. 28	MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	Jun. 28	CI
Health Care Stocks Fall With Broad Market -- Health Care Roundup	Jun. 27	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	Jun. 27	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	Jun. 27	MT
AbbVie: acquisition of Celsius for $250 million	Jun. 27	CF
AbbVie Buys Celsius Therapeutics for $250 Million	Jun. 27	DJ